HTB

TB coinfection

Tuberculosis treatment pipeline

Tuberculosis vaccine pipeline

Maternal TB, HIV and pregnancy

Overview of TB-related studies at IAS

TMC207 reduces time to sputum conversion in phase II trial on patients with drug-resistant TB

High rate of lost and untested TB biopsy samples and low screening for latent TB

Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin

PI-based ART in children with HIV and HIV/TB coinfection in South Africa

Nevirapine: fluconazole and TB treatment

WHO global TB control report highlights that 25% of TB-related deaths occur in HIV-positive people

Lack of efficacy of isoniazid (INH) prophylaxis and PK evaluation in South African infants

Treatment outcomes in patients who received rifampicin with nevirapine or efavirenz

HIV and TB co-infection and treatment charges in the UK

Long-term effectiveness of isoniazid prophylaxis on TB incidence in a cohort of IDUs

Plasma concentrations of efavirenz and lopinavir in children with and without rifampicin-based TB treatment

Extensively drug resistant TB (XTB) in South Africa

Extensively drug resistant tuberculosis: a serious wake-up call for global health

Global report on TB and HIV: new analysis of TB/HIV epidemics in Bangladesh, Brazil, Nigeria, Tanzania, and Thailand

HIV linked to lower rifampin and ethambutol AUCs in TB cohort

Dosing rifabutin and lopinavir/r – sub-optimal rifabutin levels reported in five patients dosed according to current guidelines

Tuberculosis in HIV-positive children often missed from incidence data: the influence of HAART on paediatric TB

NICE publishes TB guidelines in UK

WHO launches new stop TB strategy

Incidence of TB infection despite HAART and treatment in coinfected patients

Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients

Efavirenz and rifampicin: lower body weight associated with higher concentrations

Responses to TB treatment in HIV positive and HIV negative patients in the UK

800mg efavirenz may not be needed with rifampicin-based TB regimens, especially in African patients

Steady state PK of nelfinavir and M8 in pregnancy

CDC study shows rifampin/pyrazinamide therapy can cause severe liver damage

New antibiotic appears effective against MDR-TB

New TB blood test shows promise

Coinfection does not appear to augment TB infectivity

Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection

Post navigation